FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, more specifically to oncology, and concerns the use of CD151 antibodies for treating primary tumours. What is offered is the use of at least one antibody or one of its functional fragments able to bind to CD151 protein and to inhibit tumour cell growth for preparing a therapeutic agent for treating primary tumours. There are also presented a composition for treating primary tumours containing said antibody or its functional fragment as an active principle, and the use of said composition for preparing the drug for treating primary tumours. In a particular case, the CD151 antibody represents a monoclonal TS151 or TS 151r antibody.
EFFECT: group of inventions provides the new therapeutic agent for treating primary tumours possessing an ability to inhibit developing tumours at the early stages.
20 cl, 9 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST RESISTANCE ANTIGEN, ANTIBODIES PRODUCED BY SAME METHOD AND USING THEM | 2007 |
|
RU2515904C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
